Sarepta Therapeutics Inc. (SRPT)

130.25 +0.67 (+0.517%)

IEX Real-Time Price

August 17, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 129.58

Price Open 130.01

Volume: 732,693

Avg Volume: 1.01M

Market Cap: 8.65B

P/E Ratio -57.89

52 Wk Range 35.26-176.5



SRPT Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
50.96M
9.12M
9.55
17.89%

2018-07-13
50.05M
9.6M
3.53
19.18%

2018-06-29
50.05M
9.8M
3.56
19.59%

2018-06-15
50.06M
9.99M
7.71
19.96%




SRPT Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-03
Q1 2018
AMC
-0.48 (9)
-0.44
0.04

2018-04-26
Q1 2018
N/A
-0.32 (9)
0.00
0.00

2018-03-01
Q4 2017
AMC
-0.35 (10)
-0.37
-0.06

2018-02-27
Q4 2017
N/A
-0.36 (9)
-0.37
-0.06

News

United Rentals Should Go Up - Cramer's Lightning Round (8/16/18) (2018-08-17 07:26 SeekingAlpha)

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, August 16. Bullish Calls Royal Dutch Shell (RDS.A): Everybody is crazy about oil going from $70 to $80. It's time to buy Royal Dutch. Ebix Inc. (EBIX): Cramer likes this software company dedica…

 


Statistics

Shares Outstanding: 66.44M

Top 15 Institution Percent: 88.50

Price To Sales: 35.67

Price To Book: 12.38

Revenue: 45.95M

Gross Profit: 42.88M

Cash: 617.63M

Debt: 31.28M

Return On Assets: -25.49

Return On Equity: -40.19

Profit Margin: -89.64

Price History

Beta: 1.23

50-day Moving Avg: 126.59

200-day Moving Avg: 83.29

YTD Change: 123.61

5-day Change: 2.40

1-month Change: -5.13

3-month Change: 41.81

6-month Change: 107.17

1-year Change: N/A

Revenue Per Share: 1.00

Revenue Per Employee: 180212.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Sarepta Therapeutics Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.